Table 4: Kappa statistics and 95% confidence interval for the concordance between the JIS, IDF, and ATPIII 2005 metabolic syndrome criteria presented by gender and HIV-related subgroups ().

Group and subgroupCriteriaIDFJIS

Overall ()IDF0.96 (0.93–0.98)
ATPIII 20050.84 (0.80–0.89)0.89 (0.86–0.93)
MenIDF0.79 (0.65–0.93)
ATPIII 20050.62 (0.43–0.81)0.88 (0.77–0.98)
WomenIDF0.98 (0.96–1.00)
ATPIII 20050.87 (0.83–0.92)0.89 (0.85–0.93)
HIV duration—overall ()IDF0.96 (0.93–0.98)
ATPIII 20050.84 (0.80–0.89)0.89 (0.85–0.93)
 yrsIDF0.96 (0.92–0.99)
ATPIII 20050.81 (0.73–0.89)0.86 (0.79–0.92)
 yrsIDF0.95 (0.92–0.99)
ATPIII 20050.86 (0.80–0.92)0.91 (0.87–0.95)
CD4 count—overall ()IDF0.99 (0.97–1.00)
ATPIII 20050.89 (0.84–0.94)0.91 (0.86–0.95)
CD4 cells/mm3IDF0.99 (0.96–1.00)
ATPIII 20050.86 (0.78–0.95)0.88 (0.80–0.96)
CD4 cells/mm3IDF0.99 (0.96–1.00)
ATPIII 20050.91 (0.85–0.98)0.93 (0.87–0.98)
Antiretroviral therapy use—overall ()IDF0.95 (0.93–0.98)
ATPIII 20050.85 (0.81–0.90)0.90 (0.87–0.94)
No antiretroviral treatmentIDF0.95 (0.86–1.00)
ATPIII 20050.9 (0.77–1.00)0.95 (0.86–1.00)
On antiretroviral treatmentIDF0.95 (0.93–0.98)
ATPIII 20050.85 (0.80–0.90)0.90 (0.86–0.94)
1st-line antiretroviral therapy regimenIDF0.96 (0.93–0.99)
ATPIII 20050.86 (0.80–0.92)0.91 (0.86–0.95)
2nd-line antiretroviral therapy regimenIDF0.91 (0.81–1.00)
ATPIII 20050.85 (0.72–0.98)0.94 (0.86–1.00)
Other antiretroviral therapy regimensIDF0.95 (0.90–1.00)
ATPIII 20050.81 (0.71–0.91)0.86 (0.77–0.95)

ATPIII: Adult Treatment Panel III; IDF: International Diabetes Federation; JIS: Joint Interim Statement; HIV: human immunodeficiency virus. Data were missing for some characteristics. For each grouping variable for which data were missing for some participants, the overall agreement between criteria in that subsample is provided.